{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-004524","form_type":"8-K","ticker":"COR","cik":"0001140859","company_name":"Cencora, Inc.","filed_at":"2026-01-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.610271+00:00","generated_at":"2026-05-16T09:44:17.386775+00:00","sec_items":["1.01","2.03","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cencora secures $5.5B in financing for OneOncology acquisition; $4.5B bridge replaced","bullets":["Revolving credit facility increased by $1.0B to $5.5B via amendment on Jan 12, 2026.","Entered $1.5B term loan facility ($500M Tranche One, $1.0B Tranche Two) to fund acquisition.","Entered $3.0B 364-day term loan facility to pay consideration and fees for acquisition.","Existing $4.5B bridge financing automatically reduced to zero upon new facilities.","Interest margins range from 75-125 bps over SOFR; leverage covenant max 4.00x with potential increase to 4.50x."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-004524","json":"https://secwatch.observer/filing/0001104659-26-004524.json","markdown":"https://secwatch.observer/filing/0001104659-26-004524.md","text":"https://secwatch.observer/filing/0001104659-26-004524.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1140859/000110465926004524/0001104659-26-004524-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1140859/000110465926004524/tm263332d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T09:44:17.386775+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4032302bf5148bd5c954c904251ed5ceb2bc633b","claim":"Cencora, Inc. amended revolving credit of by $1.0 billion to $5.5 billion with JPMorgan Chase Bank, N.A., as administrative agent.","evidence_excerpt":"The Amendment increased the aggregate amount of the commitments under the Revolving Credit Agreement by $1.0 billion to $5.5 billion.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1140859/000110465926004524/0001104659-26-004524-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"revolving credit"},{"label":"Principal","value":"by $1.0 billion to $5.5 billion"},{"label":"Counterparty","value":"JPMorgan Chase Bank, N.A., as administrative agent"},{"label":"Event","value":"amendment"}],"fact_type":"debt_financing"},{"claim_id":"872c3298145ae13c08be3998c8d902683f13da37","claim":"Cencora, Inc. incurred term loan of $1.5 billion with JPMorgan Chase Bank, N.A., as administrative agent at a rate equal to either a Term SOFR rate or a Daily Simple SOFR rate, plus an app maturing Tranche One Loans mature two years from the date on which they are drawn. Tranche Two Loans mature three years from the date on which they are drawn.","evidence_excerpt":"On January 12, 2026, the Company entered into a Term Credit Agreement (the \"Term Credit Agreement\"), among the Company, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent, in connection with the previously announced proposed acquisition (the \"Acquisition\") of the majority of the outstanding equity interests that the Company does not currently own in OneOncology. The Term Credit Agreement provides for a senior unsecured term loan facility of $1.5 billion consisting of two tranches: (a) $500 million (\"Tranche One Loans\") and (b) $1.0 billion (\"Tranche Two Loans\" and together with Tranche One Loans, the \"Term Loans\").","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1140859/000110465926004524/0001104659-26-004524-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"term loan"},{"label":"Principal","value":"$1.5 billion"},{"label":"Counterparty","value":"JPMorgan Chase Bank, N.A., as administrative agent"},{"label":"Rate","value":"a rate equal to either a Term SOFR rate or a Daily Simple SOFR rate, plus an app"},{"label":"Maturity","value":"Tranche One Loans mature two years from the date on which they are drawn. Tranche Two Loans mature three years from the date on which they are drawn"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"dd8fdb344cd25ba7767b2f978c678436ba0868a4","claim":"Cencora, Inc. incurred term loan of $3.0 billion with Citibank, N.A., as administrative agent at a rate equal to either a Term SOFR rate or a Daily Simple SOFR rate, plus an app maturing The 364-Day Term Loan matures 364 days from the date on which it is drawn.","evidence_excerpt":"On January 12, 2026, the Company entered into a Credit Agreement (the \"364-Day Term Credit Agreement\"), among the Company, the lenders party thereto and Citibank, N.A., as administrative agent, in connection with the Acquisition. The 364-Day Term Credit Agreement provides for a senior unsecured term loan facility of $3.0 billion (the \"364-Day Term Loan\").","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1140859/000110465926004524/0001104659-26-004524-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"term loan"},{"label":"Principal","value":"$3.0 billion"},{"label":"Counterparty","value":"Citibank, N.A., as administrative agent"},{"label":"Rate","value":"a rate equal to either a Term SOFR rate or a Daily Simple SOFR rate, plus an app"},{"label":"Maturity","value":"The 364-Day Term Loan matures 364 days from the date on which it is drawn"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"71751867f301d9a6a77d5f95545fb1d087110dbd","claim":"Cencora, Inc. amended Incremental Facility and Amendment Agreement with JPMorgan Chase Bank, N.A. valued at $1.0 billion (effective 2026-01-12).","evidence_excerpt":"On January 12, 2026, Cencora, Inc. (the “Company”) entered into an Incremental Facility and Amendment Agreement (the “Amendment”) to that certain Amended and Restated Credit Agreement (as amended by the Amendment, the “Revolving Credit Agreement”), dated as of June 4, 2025, among the Company, the borrowing subsidiaries party thereto, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1140859/000110465926004524/0001104659-26-004524-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"JPMorgan Chase Bank, N.A."},{"label":"Value","value":"$1.0 billion"},{"label":"Effective","value":"2026-01-12"}],"fact_type":"material_agreement"},{"claim_id":"ad243984b6ff6b0f7999427aabc7ca964d4ea49c","claim":"Cencora, Inc. entered into 364-Day Term Credit Agreement with Citibank, N.A. valued at $3.0 billion (effective 2026-01-12).","evidence_excerpt":"On January 12, 2026, the Company entered into a Credit Agreement (the “364-Day Term Credit Agreement”), among the Company, the lenders party thereto and Citibank, N.A., as administrative agent, in connection with the Acquisition.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1140859/000110465926004524/0001104659-26-004524-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Citibank, N.A."},{"label":"Value","value":"$3.0 billion"},{"label":"Effective","value":"2026-01-12"}],"fact_type":"material_agreement"},{"claim_id":"f3c6612336bbd5fc4350eb95c73d32be9554b071","claim":"Cencora, Inc. entered into Term Credit Agreement with JPMorgan Chase Bank, N.A. valued at $1.5 billion (effective 2026-01-12).","evidence_excerpt":"On January 12, 2026, the Company entered into a Term Credit Agreement (the “Term Credit Agreement”), among the Company, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent, in connection with the previously announced proposed acquisition (the “Acquisition”) of the majority of the outstanding equity interests that the Company does not currently own in OneOncology.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1140859/000110465926004524/0001104659-26-004524-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"JPMorgan Chase Bank, N.A."},{"label":"Value","value":"$1.5 billion"},{"label":"Effective","value":"2026-01-12"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}